Navigation Links
ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
Date:8/19/2007

ofessional as a 30-minute intravenous infusion at a fixed dose based on body weight range approximating 10 mg/kg at day 0, 2 weeks, 4 weeks, and every 4 weeks thereafter. Acute infusion-related reactions were experienced in nine percent of people treated with ORENCIA and in six percent of people treated with placebo. According to the full prescribing information, the most frequently reported infusion- related adverse events (1 percent to 2 percent) were dizziness, headache, and hypertension. In pivotal studies, premedications were not required. However, appropriate medical support measures for the treatment of hypersensitivity reactions should be available for immediate use in the event of a reaction.

About ORENCIA(R) (abatacept)

ORENCIA is currently indicated in the United States for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more DMARDs, such as methotrexate or TNF antagonists. ORENCIA may be used as monotherapy or concomitantly with DMARDs other than TNF antagonists. ORENCIA should not be administered concomitantly with TNF antagonists and is not recommended for use concomitantly with anakinra.

Bristol-Myers Squibb Company is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.


'/>"/>
SOURCE Bristol-Myers Squibb Company

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. Materia Licenses Metathesis Catalyst Platform to Eisai
4. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
5. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
6. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
7. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
8. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
9. New Quality Control Systems for Every Laboratory Application
10. Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor AP 12009 to be Presented
11. Antares Pharma Announces Positive Results from Application Site Study for Anturol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Oct. 24, 2014  Heska Corporation (Nasdaq: ... You to Join Its Third Quarter 2014 Earnings Conference ... a.m. (MDT) / 11:00 a.m. (EDT)Where: , www.heska.com ... on the front page of this website)How:Live over the ... the address above.  Alternatively, you may use the following ...
(Date:10/25/2014)... , Oct. 24, 2014  The National Association ... latest results achieved by Kentucky,s ... The National Precursor Log Exchange (NPLEx) ... point of sale and helps flag meth offenders ... often set up NPLEx "watch lists" that notify ...
(Date:10/25/2014)... 2014   Metanome, Inc. , a ... data analysis, was the genomic sequencing provider for Seres ... clinical trial of SER 109, an Ecobiotic® therapeutic for ... infections (CDI). Metanome has provided genomic ... clinical programs. Such genomic characterization has enabled the study ...
Breaking Medicine Technology:Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast 2Kentucky's NPLEx Technology Making Significant Progress 2Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2
... 2, 2012  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... Marketing Authorization Application (MAA) with the European Medicines Agency ... weight control, including weight loss and maintenance of weight ... patients who are overweight (BMI >27) and have at ...
... 2012 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord ... leading specialty hospital management solution provider and operator ... imaging centers in China, today announced it will release ... full year 2011 after the market closes, at ...
Cached Medicine Technology:Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control 2Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control 3Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control 4Concord Medical to Report Fourth Quarter and Full Year 2011 Financial Results on March 21, 2012 2
(Date:10/25/2014)... (PRWEB) October 25, 2014 Background: , ... Recovery (CCAR). He is a pioneer in the field of ... in Connecticut's state treatment system and when he retired, he ... him while in public service. , 1. ... critical decisions concerning them? , 2. Can the recovery ...
(Date:10/25/2014)... 25, 2014 Market Research ... Industry, 2009-2019 is a professional and in-depth ... Diagnostics industry. The report firstly reviews the ... classification, application and manufacturing technology. The report ... of Molecular Diagnostics listing their product specification, ...
(Date:10/25/2014)... 2014 The federal judge overseeing ... ) filed against Boston Scientific Corp. in the ... Southern District of West Virginia has denied a ... in a group of cases filed on behalf ... October 21st, U.S. District Judge Joseph R. Goodwin ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Interrupting blood supply to ... reduce the risks associated with the surgery, according to a ... stop the blood supply to the heart to be able ... the heart will reduce its ability to produce energy because ... flow to another large muscle, such as an arm or ...
(Date:10/25/2014)... Researchers who discovered antibiotics in farmed and wild ... The use of antibiotics in animals, including ... to the development of antibiotic-resistant bacteria that threaten ... study. Each year in the United States, ... kill about 23,000, according to the Infectious Diseases ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2
... is not a luxury;,it is an activity that is ... survey analysis of 30 companies and in-depth interviews,with seven ... in a,difficult economy., The complete study addresses areas ... goals of benchmarking studies, how companies are,demonstrating value through ...
... chemical serotonin influences fat metabolism , , THURSDAY, June 5 ... a frustrating truism familiar to the diet-conscious choosing between ... weight control isn,t just a matter of what you ... system is genetically predisposed to process fat. , The ...
... Forum to Explore Solutions Presented by The Massachusetts ... 5 "We are greatly,concerned in this state about ... of our returning veterans, the stress, depression and ... specter of rising levels of,domestic violence and suicide. ...
... The U. S. Army Corps of,Engineers, in partnership ... and recreation industry partners, will,participate in the first ... On this day, more than 75 organizations will ... privately-managed recreation sites,across the country according to event ...
... and ... more, ... and figure competitors Allison,Frahn and Tina Durkin, will represent GNC at the ... in Atlanta., Chad, part of the World Natural Bodybuilding Federation (WNBF), ...
... top equine veterinarians perform leading-edge techniques and,identify ... lives of both,horses and humans, WASHINGTON, ... Research (FBR) releases its feature film Majestic ... Dr. Larry Bramlage (Rood & Riddle,Equine Hospital) ...
Cached Medicine News:Health News:Demonstrating the Value of Benchmarking in an Uncertain Economy 2Health News:Weight Gain May Not Be Based Just on What You Eat 2Health News:Weight Gain May Not Be Based Just on What You Eat 3Health News:Growing Public Health Crisis of Domestic Violence and Suicides by Returning Veterans 2Health News:Army Corps of Engineers Will Host National Get Outdoors Day Activities at Six Corps Project Sites 2Health News:Rite Aid Health and Beauty Expo to Showcase GNC Athletes 2Health News:The Foundation for Biomedical Research (FBR) Releases Feature DVD Majestic for World Premiere 2